Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program

Peter Iversen, Manfred P Wirth, William A See, David G McLeod, Ira Klimberg, Donald Gleason, Gerald Chodak, James Montie, Chris Tyrrell, D M A Wallace, Karl P J Delaere, Per Lundmo, Teuvo L J Tammela, Jan-Erik Johansson, Tom Morris, Kevin Carroll, Casodex Early Prostate Cancer Trialists' Group

    16 Citationer (Scopus)

    Abstract

    To report an exploratory subgroup analysis assessing the extent to which the overall benefit found in the Early Prostate Cancer program is dependent on lymph node status at randomization. The program is ongoing, and the overall survival data are immature. The first combined analysis of the bicalutamide (Casodex) Early Prostate Cancer program at 3 years' median follow-up showed that bicalutamide, 150 mg once daily, plus standard care (radical prostatectomy, radiotherapy, or watchful waiting), significantly reduced the risk of objective progression and prostate-specific antigen (PSA) doubling in patients with localized/locally advanced prostate cancer.
    OriginalsprogEngelsk
    TidsskriftUrology
    Vol/bind63
    Udgave nummer5
    Sider (fra-til)928-33
    Antal sider6
    ISSN0090-4295
    DOI
    StatusUdgivet - 1 maj 2004

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program'. Sammen danner de et unikt fingeraftryk.

    Citationsformater